Advertisement

Neuroscience and Behavioral Physiology

, Volume 49, Issue 1, pp 147–152 | Cite as

Studies of the Efficacy of Cereton in Mild Cognitive Impairment of the Amnestic Type Based on Testing Lipid Markers

  • A. V. AlesenkoEmail author
  • S. I. Gavrilova
  • U. A. Gutner
  • A. O. Lebedeva
  • M. A. Shupik
  • I. V. Kolykhalov
  • E. V. Ponomareva
  • N. D. Selezneva
  • Ya. B. Fedorova
Article
  • 2 Downloads

Objectives. To determine the efficacy and safety of treatment with Cereton (alfoscerate) in patients with mild cognitive impairment syndrome (MCI) and its effects during and after treatment on phosphatidyl-choline, sphingomyelin, and ceramide (a sphingolipids metabolite) contents and the activity of genes controlling the synthesis of enzymes (sphingomyelinase and ceramidase) involved in the sphingomyelin and ceramide metabolism. Materials and methods. A total of 20 patients (14 women, six men) aged 51–82 (mean 70.3 ± 9.1) years were studied. Patients’ status corresponded to the criteria for diagnosis of MCI syndrome of the anamnestic type. Plasma phosphatidylcholine, sphingomyelin, and ceramide were estimated by thin layer chromatography, while expression of the sphingomyelinase and ceramidase genes was determined using the reverse transcriptase polymerase chain reaction. Results and conclusions. Sharp increases in the contents of phosphatidylcholine and ceramide – hydrolysis products of sphingomyelin – were seen. Expression of the genes (acid sphingomyelinase and ceramidase) controlling ceramide metabolism decreased in most patients during Cereton treatment. Increases in the levels of phosphatidylcholine and decreases in the expression of ceramide metabolism genes during treatment with Cereton and other agents affecting phosphatidylcholine and sphingomyelin metabolism can be used as markers for treatment efficacy.

Keywords

mild cognitive impairment (MCI) phosphatidylcholine sphingomyelin ceramide sphingomyelinase ceramidase 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. I. Gavrilova (ed.), Handbook for Geriatric Psychiatry, Pulse, Moscow (2001).Google Scholar
  2. 2.
    Ya. B. Kalyn and S. I. Gavrilova, “Dynamics of measures of the prevalence of mental disorders in the elderly and old population,” in: Reforms in Mental Health Services: Challenges and Perspectives (1997), pp. 181–189.Google Scholar
  3. 3.
    N. D. Selezneva, N. M. Mikhailova, Ya. B. Kalyn, I. F. Roshchina, and S. I. Gavrilova, “Studies of the efficacy and safety of Actovegin in elderly patients with mild cognitive impairment syndrome of cerebrovascular origin,” Psikhiatriya, 1, 37–50 (2009).Google Scholar
  4. 4.
    S. I. Gavrilova, I. V. Kolykhalov, Ya. B. Fedorova, et al., “Potentials for preventive treatment in Alzheimer’s disease: results of a three-year prospective, open, comparative trial of the efficacy and safety of courses of treatment with Cerebrolysin and Cavinton in elderly patients with mild cognitive impairment syndrome,” Zh. Nevrol. Psikhiat., 1, 68–75 (2010).Google Scholar
  5. 5.
    R. M. Adibhatla and J. F. Hatcher, “Altered lipid metabolism in brain injury and disorders,” Subcell. Biochem., 49, 241–268 (2008),  https://doi.org/10.1007/978-1-4020-8831-5_9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    L. Colombaioni and M. Garcia-Gil, “Sphingolipid metabolites in neural signalling and function,” Brain Res. Brain Res. Rev., 46, 328–355 (2004),  https://doi.org/10.1016/j.brainresrev.2004.07.014.CrossRefGoogle Scholar
  7. 7.
    A. V. Alessenko and S. V. Gurianova, “Potential role of ceramides in neurodegenerative diseases,” in: Sphingomyelin and Ceramides: Occurrence, Biosynthesis and Role in Disease, NOVA Science Publisher, New York (2015), pp. 21–53.Google Scholar
  8. 8.
    T. A. Ban, R. M. Panzarasa, S. Borra, D. Del Duchetto, and O. K. Fjetland, “Choline alphoscerate in elderly patients with cognitive decline due to dementing illness,” New Trends Clin. Neuropharmacol., 5, 1–35 (1991).Google Scholar
  9. 9.
    O. A. Shavlovskaya, “Experience in the use of Cereton (choline alfoscerate) in clinical practice,” Rus. Med. Zh., 19, No. 9, 557–561 (2011).Google Scholar
  10. 10.
    L. Parnetti, G. Abate, L. Bartorelli, et al., “Multicentre study of 1-alpha-glycerylphosphorylcholine vs ST 200 among patients with probable senile dementia of Alzheimer type,” Drugs Aging, 3, Suppl. 2, 159–164 (1993),  https://doi.org/10.2165/00002512-199303020-00006.CrossRefPubMedGoogle Scholar
  11. 11.
    E. Aguglia, T. A. Ban, R. M. Panzarasa, S. Borra, and O. K. Fietland, “Choline alphoscerate in the treatment of mental pathology following acute cerebrovascular accident,” Funct. Neurol., 8, Suppl. 3, 5–24 (1993).Google Scholar
  12. 12.
    P. L. Scapicchio, “Revisiting choline alphoscerate profile: a new perspective role in dementia,” Int. J. Neurosci., 123, 444–449 (2013),  https://doi.org/10.3109/00207454.2013.765870.CrossRefPubMedGoogle Scholar
  13. 13.
    T. V. Builova, M. E. Glotova, M. E. Khalak, and V. V. Vashkevich, “Experience in the use of Cereton in the process of rehabilitation of patients with hemorrhagic stroke,” Zh. Nevrol. Psikhiat., 5, No. 2, 58–62 (2009).Google Scholar
  14. 14.
    S. I. Gavrilova, A. V. Alesenko, I. V. Kolykhalov, et al., “Clinical-biological effects of Cereton in the treatment of mild cognitive impairment syndrome of the amnestic type,” Psikhiatriya, 73, No. 1, 5–15 (2017).Google Scholar
  15. 15.
    T. G. Bligh and W. J. Dyer, “A rapid method of total lipid extraction and purification,” Can. J. Biochem. Physiol., 37, 911–917 (1959),  https://doi.org/10.1139/o59-099.CrossRefPubMedGoogle Scholar
  16. 16.
    R. D. Duan, “Alkaline sphingomyelinase: an old enzyme with novel implications,” Biochim. Biophys. Acta, 1761, 281–291 (2006),  https://doi.org/10.1016/j.bbalip.2006.03.007.CrossRefPubMedGoogle Scholar
  17. 17.
    R. W. Jenkins, D. Canals, and Y. A. Hannun, “Roles and regulation of secretory and lysosomal acid sphingomyelinase,” Cell Signal, 21, 836–846 (2009).CrossRefGoogle Scholar
  18. 18.
    Z. F. Yu, M. Nikolova-Karakahian, D. Zhou, et al., “Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis,” J. Mol. Neurosci., 15, 85–97 (2000),  https://doi.org/10.1385/JMN:15:2:85.CrossRefPubMedGoogle Scholar
  19. 19.
    N. Bartke and Y. A. Hannun, “Bioactive sphingolipids: metabolism and functions,” J. Lipid Res., 50, supplement, 91–96 (2009),  https://doi.org/10.1194/jlr.R800080-JLR200.
  20. 20.
    M. Maceyka, K. B. Harikumar, S. Milstein, and S. Spiegel, “Sphingosine-1-phosphate signaling and its role in disease,” Trends Cell Biol., 22, 50–60 (2012),  https://doi.org/10.1016/j.tcb.2011.09.003.CrossRefPubMedGoogle Scholar
  21. 21.
    C. Mao and L. V. Obeid, “Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate,” Biochim. Biophys. Acta, 1781, 424–434 (2008),  https://doi.org/10.1016/j.bbalip.2008.06.002.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    P. Katsel, C. Li, and V. Haroutunian, “Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease?” Neurochem. Res., 32, 845–856 (2007),  https://doi.org/10.1007/s11064-007-9297-x.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • A. V. Alesenko
    • 1
    Email author
  • S. I. Gavrilova
    • 2
  • U. A. Gutner
    • 1
  • A. O. Lebedeva
    • 1
  • M. A. Shupik
    • 1
  • I. V. Kolykhalov
    • 2
  • E. V. Ponomareva
    • 2
  • N. D. Selezneva
    • 2
  • Ya. B. Fedorova
    • 2
  1. 1.Institute of Biochemical PhysicsRussian Academy of SciencesMoscowRussia
  2. 2.Scientific Center for Mental HealthMoscowRussia

Personalised recommendations